The BCR-ABL1 fusion protein activates the PI3K-Akt signaling pathway in CML, which is crucial for promoting leukemic cell proliferation, survival, and metabolism, thereby contributing to the progression of CML [29]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.